CHEK1 and neoplasm: In summary, these preclinical studies demonstrate that V158411 is a potent, selective inhibitor of Chk1 that, in vivo, is well tolerated and enhances the anti-tumor activity of irinotecan therapy with a schedule that will be easily transferable to the clinic.